Cargando…

Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis

PURPOSE: The purpose of this study is to compare the different EGFR mutation status in patients with metastatic non-small cell lung cancer (NSCLC) after first-line EGFR-TKIs therapy and analyze its relationship with efficacy and prognosis. PATIENTS AND METHODS: This study retrospectively analyzed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Chengliang, Jiang, Huiqin, Jiang, Wei, Wang, Huilin, Su, Cuiyun, Zhou, Shaozhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423412/
https://www.ncbi.nlm.nih.gov/pubmed/34512029
http://dx.doi.org/10.2147/CMAR.S329900
_version_ 1783749460308787200
author Yuan, Chengliang
Jiang, Huiqin
Jiang, Wei
Wang, Huilin
Su, Cuiyun
Zhou, Shaozhang
author_facet Yuan, Chengliang
Jiang, Huiqin
Jiang, Wei
Wang, Huilin
Su, Cuiyun
Zhou, Shaozhang
author_sort Yuan, Chengliang
collection PubMed
description PURPOSE: The purpose of this study is to compare the different EGFR mutation status in patients with metastatic non-small cell lung cancer (NSCLC) after first-line EGFR-TKIs therapy and analyze its relationship with efficacy and prognosis. PATIENTS AND METHODS: This study retrospectively analyzed the data of patients with metastatic NSCLC harboring EGFR mutation in the Affiliated Tumor Hospital of Guangxi Medical University from June 2016 to December 2020. Samples were collected before treatment and at the time of disease progression after first-line EGFR-TKIs therapy. Amplification refractory mutation system (ARMS) PCR and next-generation sequencing (NGS) were used to detect EGFR mutation. ORR, DCR, and PFS of different EGFR mutation groups were compared. RESULTS: The EGFR mutation rate of re-biopsy was 60.23%. The inconsistency rate of EGFR mutations in the same and different simple types was 72.22% (26/36) and 92.31% (48/52), respectively. Alterations in terms of EGFR mutations were divided into four groups: Group A: EGFR-sensitive mutation negative and T790M negative (39.77%); Group B: EGFR-sensitive mutation positive and T790M negative (18.19%); Group C: EGFR-sensitive mutation negative and T790M positive (36.36%); Group D: EGFR-sensitive mutation positive and T790M positive (5.68%). The differences between the four groups in ORR and DCR were not statistically significant (P>0.05). The median PFS of all patients was 10.65 months. PFS of Group A, B, C, and D was 12.26, 7.96, 10.55, and 13.81 months, respectively, with statistical significance (Log rank P = 0.014). CONCLUSION: EGFR mutation status in metastatic NSCLC patients receiving the first- and second-generation TKIs after disease progression show diversity. Monitoring the EGFR mutation changes is of great importance for subsequent clinical decision-making and exploring the underlying mechanisms of acquired resistance.
format Online
Article
Text
id pubmed-8423412
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84234122021-09-09 Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis Yuan, Chengliang Jiang, Huiqin Jiang, Wei Wang, Huilin Su, Cuiyun Zhou, Shaozhang Cancer Manag Res Original Research PURPOSE: The purpose of this study is to compare the different EGFR mutation status in patients with metastatic non-small cell lung cancer (NSCLC) after first-line EGFR-TKIs therapy and analyze its relationship with efficacy and prognosis. PATIENTS AND METHODS: This study retrospectively analyzed the data of patients with metastatic NSCLC harboring EGFR mutation in the Affiliated Tumor Hospital of Guangxi Medical University from June 2016 to December 2020. Samples were collected before treatment and at the time of disease progression after first-line EGFR-TKIs therapy. Amplification refractory mutation system (ARMS) PCR and next-generation sequencing (NGS) were used to detect EGFR mutation. ORR, DCR, and PFS of different EGFR mutation groups were compared. RESULTS: The EGFR mutation rate of re-biopsy was 60.23%. The inconsistency rate of EGFR mutations in the same and different simple types was 72.22% (26/36) and 92.31% (48/52), respectively. Alterations in terms of EGFR mutations were divided into four groups: Group A: EGFR-sensitive mutation negative and T790M negative (39.77%); Group B: EGFR-sensitive mutation positive and T790M negative (18.19%); Group C: EGFR-sensitive mutation negative and T790M positive (36.36%); Group D: EGFR-sensitive mutation positive and T790M positive (5.68%). The differences between the four groups in ORR and DCR were not statistically significant (P>0.05). The median PFS of all patients was 10.65 months. PFS of Group A, B, C, and D was 12.26, 7.96, 10.55, and 13.81 months, respectively, with statistical significance (Log rank P = 0.014). CONCLUSION: EGFR mutation status in metastatic NSCLC patients receiving the first- and second-generation TKIs after disease progression show diversity. Monitoring the EGFR mutation changes is of great importance for subsequent clinical decision-making and exploring the underlying mechanisms of acquired resistance. Dove 2021-09-03 /pmc/articles/PMC8423412/ /pubmed/34512029 http://dx.doi.org/10.2147/CMAR.S329900 Text en © 2021 Yuan et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yuan, Chengliang
Jiang, Huiqin
Jiang, Wei
Wang, Huilin
Su, Cuiyun
Zhou, Shaozhang
Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
title Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
title_full Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
title_fullStr Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
title_full_unstemmed Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
title_short Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
title_sort comparison of different egfr gene mutation status in patients with metastatic non-small lung cancer after first-line egfr-tkis therapy and analyzing its relationship with efficacy and prognosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423412/
https://www.ncbi.nlm.nih.gov/pubmed/34512029
http://dx.doi.org/10.2147/CMAR.S329900
work_keys_str_mv AT yuanchengliang comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis
AT jianghuiqin comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis
AT jiangwei comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis
AT wanghuilin comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis
AT sucuiyun comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis
AT zhoushaozhang comparisonofdifferentegfrgenemutationstatusinpatientswithmetastaticnonsmalllungcancerafterfirstlineegfrtkistherapyandanalyzingitsrelationshipwithefficacyandprognosis